Supplemental Figure 12. from Comprehensive Multiplatform Tyrosine Kinase Profiling Reveals Novel Actionable FGFR Aberrations across Sarcomas Affecting the Young
Year: 2026
Type: supplementary-materials
Abstract: A) Rh30 SPRY2 KO models were generated using CRISPR-Cas9. Bulk cell populations were single cell sorted to select clonal populations (2, 5, 7) with complete knockout, which was confirmed by Western blot analysis. Complete KO was observed in clone 7 and as such this was used for further functional studies. B) Cell cycle analysis of Rh30 SPRY2 knockout clone 7 and Cas-9 control treated for 8-hours with 10 μM lenvatinib, erdafitinib or FGF401. Data presented as the percentage of drug-treated cells in G1, S and G2 phase normalized to untreated control of each respective cell line construct +/- SEM (n=3). C) Colony assay following two-weeks of 10 μM erdafitinib, FGF401 or lenvatinib treatment in the presence or absence of 20 ng/mL FGF8. NB FGF8-treated cells were prior to this experiment preconditioned with FGF8 for two weeks. Data presented as mean colony number +/- SEM (n=3). **: P < 0.01 when compared to untreated control (one-way ANOVA with Tukey multiple-comparisons test). D) Representative images of colony assay (n=3 from C).
Authors: Ashleigh M. Fordham, Lauren M. Brown, Chelsea Mayoh, Alice Salib, Zara A. Barger, Marie Wong, Terry C.C. Lim Kam Sian, Changyuan Hu, Jinhan Xie, Kate Gunther, Peter Trebilcock, Rachael L. Terry, Paulette Barahona, Pamela Ajuyah, Alexandra Sherstyuk, Anica Avila, Roxanne Cadiz, Callum M. Perkins, Andrew J. Gifford, Jie Mao, M. Emmy M. Dolman, Andrea Zhao, Luke P. O’Regan, Daniel Gorgels, Loretta M.S. Lau, David S. Ziegler, Michelle Haber, Vanessa Tyrrell, Richard B. Lock, Mark J. Cowley, Wayne Nicholls, Roger J. Daly, Paul G. Ekert, Emmy D.G. Fleuren
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W7167037376